AVTX 009
Alternative Names: AVTX-009Latest Information Update: 10 Oct 2024
At a glance
- Originator Eli Lilly and Company
- Developer Avalo Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Phase I Autoimmune disorders